CLDN6-Specific CAR-T Cells plus Amplifying RNA Vaccine in Relapsed or Refractory Solid Tumors: The Phase I BNT211-01 Trial

Scientists reported dose escalation results from the ongoing phase I/II BNT211-01 trial evaluating the safety and feasibility of CAR T cells targeting the Claudin 6 (CLDN6) with or without a CAR-T cell-amplifying RNA vaccine at two dose levels in relapsed/refractory CLDN6-positive solid tumors.